Guggenheim maintains Buy rating on Damora Therapeutics, $60 price target
Guggenheim maintained their Buy rating on Damora Therapeutics's stock with a price target of $60.00.The price target implies an upside of 196.0% from the Sep 24 close of $20.27.Key takeaways from the analyst noteOptimized Therapy Potential: Damora Therapeutics is advancing a new generation of biolo…